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Searching for proteins in platelets that can interact
with the N-terminal SH3 domain of CrkL (using a com-
bination of a pull-down assay followed by mass spec-
trometry), we have found that human platelets express
an ADP-ribosylation factor (Arf)-specific GTPase-acti-
vating protein (GAP), ASAP1, as a CrkL-binding protein.
In spreading platelets, most endogenous ASAP1 is local-
ized at peripheral focal adhesions. To determine the
physiologic significance of the CrkL-ASAP1 association,
we overexpressed CrkL, ASAP1, or both in combination
in COS7 cells. Unlike endogenous ASAP1 in platelets,
overexpressed ASAP1 showed diffuse cytoplasmic dis-
tribution. However, when co-expressed with wild-type
CrkL, both endogenous and expressed ASAP1 accumu-
lated at CrkL-induced focal adhesions. An SH2-mutated
CrkL, which cannot localize at focal adhesions, failed to
recruit ASAP1 into focal adhesions. Thus, CrkL appears
to be a lynchpin between ASAP1 and peripheral focal
adhesions.
CrkL is a Src homology (SH)21 and SH3 adapter (1–3).
Through its SH2 domain, CrkL binds to focal adhesions pro-
teins like paxillin and Cas (1–3). CrkL also binds to a Rap-
specific guanine nucleotide exchange factor, C3G, through its
N-terminal SH3 domain and, thus, conveys C3G to focal adhe-
sions. C3G activates a small GTPase Rap1 and regulates cell
adhesion and spreading, indicating that the CrkL-C3G complex
is a critical component of focal adhesions (4). We previously
reported that CrkL is present in human platelets, and that it is
an adapter for WASP, syk, or phosphorylated STAT5 (5–7).
On the other hand, ADP-ribosylation factors (Arfs) are also
members of the Ras-related small GTPases and function in the
regulation of membrane trafficking and actin cytoskeleton (8,
9). Similar to other GTPases, the activity of Arfs is regulated
positively by GEFs and negatively by GTPase-activating pro-
teins (GAPs). Recently, several Arf GAPs have been cloned and
characterized and found to have phosphoinositide-dependent
GAP activity toward Arfs (10). ASAP1 (also called DEF-1,
for differentiation enhancing factor-1), the prototype of the
phosphoinositide-dependent Arf GAP family, is a multidomain
protein with pleckstrin homology, Arf GAP, ankyrin repeat, pro-
line-rich region, and SH3 domains. ASAP1 binds to phosphati-
dylinositol (4, 5)P2 through its PH domain and shows GAP activ-
ity toward Arf (11–13). In NIH3T3 cells, endogenous ASAP1
localizes in focal adhesions and, when overexpressed, ASAP1
affects cell spreading of NIH3T3 cells on fibronectin (14). Al-
though the function of Arf in focal adhesions is not clear yet, the
localization of ASAP1 and its effect on cell spreading suggests the
importance of Arf signaling on the dynamics of focal adhesions.
During our continual efforts to clarify the role of CrkL in the
regulation of signal transduction, we found that the SH3 do-
main of CrkL binds to ASAP1. The data obtained from studies
using platelets and COS7 cells overexpressing ASAP1 revealed
that CrkL is a critical lynchpin between ASAP1 and focal
adhesions.
EXPERIMENTAL PROCEDURES
Blood from healthy volunteers, after obtaining written informed
consent, was drawn by venipuncture into a one-tenth volume of 3.8%
(w/v) trisodium citrate and gently mixed. Alternatively, buffy coat,
provided by the Hokkaido Red Cross Blood Center (Sapporo, Japan),
was used instead of whole blood. Washed human platelets were pre-
pared as described previously (7) and suspended in a modified Hepes-
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Tyrode buffer (129 mM NaCl, 8.9 mM NaHCO3, 0.8 mM KH2PO4, 2 mM
KCl, 0.8 mM MgCl2, 5.6 mM dextrose, and 10 mM Hepes, pH 7.4) at a
concentration of 3  108 cells/ml with apyrase (2 units/ml) at 37 °C.
Specific affinity-purified anti-ASAP1 antibody (642) was prepared as
previously described (12). Anti-ASAP1, anti-phospho-FAK, and anti-
paxillin (cross-reactive with Hic-5) monoclonal antibodies were from
Transduction Laboratories (Jackson, KY). Anti-CrkL and anti-C3G
polyclonal antibodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). An anti-CrkL monoclonal antibody was from Upstate Technologies
(Lake Placid, NY). An anti-FLAG monoclonal antibody, thrombin, and
other reagents were from Sigma.
Immunoprecipitation and Immunoblotting—Platelets in suspension
(0.5 ml) were lysed by the addition of an equal amount of lysis buffer (15
mM Hepes, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 10 mM
EGTA, 1 mM sodium orthovanadate, 0.8 g/ml leupeptin, 2% Triton
X-100 (v/w), pH 7.4). Immunoprecipitation and immunoblotting using
the enhanced chemiluminesence (ECL) methods were performed as
previously described (7).
GST Binding Assays—GST-CrkL N-terminal SH3 fusion protein was
a gift from Dr. Brian J. Druker (Oregon Health Sciences University).
Production of GST fusion proteins and binding experiments using cell
lysates were performed as previously described (7). GST fusion proteins
were isolated from sonicated bacterial lysates using glutathione-Sepha-
rose beads. Coomassie Brilliant Blue-stained gels were used to normal-
ize the expression of the various GST fusion proteins.
MALDI-TOF/MS—From platelet lysates, we precipitated proteins
that bind to the N-terminal SH3 domain of CrkL. Following digestion by
trypsin, the bound proteins were analyzed by MALDI-TOF/MS using a
Voyager-DE/STR (Applied Biosystems, Foster City, CA). The proteins
were identified by comparison between the molecular weights deter-
mined by MALDI-TOF/MS and the theoretical peptide masses from the
proteins registered in NCBInr.
Isolation of Platelet Cytoskeleton—The Triton X-100-insoluble cy-
toskeleton from thrombin-stimulated platelets was isolated as previ-
ously described (15). An equal amount of lysis buffer was added to the
platelet suspensions to solubilize the platelets. After 5 min on ice, the
lysate was centrifuged at 10,000  g. The resulting pellet was washed
twice in washing buffer. For one-dimensional SDS electrophoresis, the
Triton X-100-insoluble pellets were solubilized in SDS sample buffer.
The supernatant was diluted with an equal volume of 2 concentrated
SDS sample buffer.
Ectopic Expression in COS7—The full-length cDNA of a murine
ASAP1 expression plasmid was constructed in the pCI (FLAG tag)
vector. Human CrkL cDNA, a gift from John Groffen (Children’s Hos-
pital, Los Angeles, CA), was subcloned into pCXN2 with FLAG tag and
designated as pCXN2-Flag-CrkL. SH2 mutant of CrkL, which was
mutated on codon 38, CGC (Arg) to GTC (Val), was generated by PCR,
subcloned into pCXN2 vector with FLAG tag, and designated as
pCXN2-Flag-CrkLR38V. The expression vector of FLAG tag C3G (a gift
from Dr. Michiyuki Matsuda) was described previously (4). To obtain
cell lysates, COS7 cells were transfected with 2 g of recombinant
plasmids using FuGENE 6 (Roche Diagnostics, Indianapolis, IN). The
cells were cultured in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum. After 24 h, the cells were har-
vested with SDS sample buffer and sonicated for SDS-PAGE analysis.
Alternatively, the cells were harvested with the lysis buffer as described
above for immunoprecipitation.
Localization of ASAP1 in Spread Platelets and COS7 Cells—Plate-
lets from diluted platelet-rich plasma were allowed to spread on glass
coverslips for 1 h at 37 ° or COS7 cells grown on glass coverslips were
fixed in 3.7% paraformaldehyde. Following treatment with 100 mM
Tris-HCl (pH 7.4) for 15 min, the cells were permeabilized in 0.15%
Triton X-100 for 1 min and blocked with Block Ace (Snow Brand, Tokyo)
for 30 min. The samples were incubated with primary and secondary
antibodies, and subjected to extensive washing. Alexa-labeled second-
ary antibodies and Alexa-conjugated phalloidin were purchased from
FIG. 1. Identification of ASAP1 as a
CrkL ligand in human platelets. A,
the partial amino acid sequence of human
ASAP1. The sequence was predicted from
an incomplete cDNA sequence of the
KIAA1249 clone. The underlined peptides
were identified by a mass spectrometry
analysis of the trypsin-digested 140-kDa
protein co-precipitated with GST-CrkL.
B, in vitro and in vivo interaction of CrkL
with ASAP1. Left panel, platelet proteins
co-precipitated with GST-CrkL were sep-
arated by SDS-PAGE (7.5–15% polyacryl-
amide). Western blot analysis was con-
ducted with an anti-ASAP1 polyclonal
antibody (642). Right panels, platelet ly-
sates were prepared using the detergent
buffer as described under “Experimental
Procedures,” immunoprecipitated with
anti-CrkL monoclonal antibody and sepa-
rated by SDS-PAGE (7.5–15% polyacryl-
amide). The CrkL-immunizing peptide
(30 g/ml) was added during immunopre-
cipitation as indicated. Western blot anal-
ysis was conducted with an anti-ASAP1
monoclonal antibody (upper panel) or an
anti-CrkL (lower panel) polyclonal anti-
body. HC, heavy chains of the anti-CrkL
antibody, used for immunoprecipitation.
C, translocation of ASAP1 to the cytoskel-
etal fraction upon activation of platelets
by thrombin (1 unit/ml). Platelets were
lysed with Triton X-100-EGTA buffer be-
fore (lanes 1 and 4) or after stimulation by
thrombin with (lanes 2 and 5) or without
(lanes 3 and 6) stirring. Lysates were sep-
arated by high-speed centrifugation into
soluble fractions (lanes 1–3) and insoluble
(lanes 4–6) pellets. Proteins from each
fraction were separated by SDS-PAGE
and immunoblotted with anti-ASAP1
monoclonal or anti-CrkL polyclonal anti-
bodies as indicated.
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Molecular Probes (Eugene, OR). Images were taken with an inverted
confocal laser-scanning microscope (Zeiss LSM 510) with a 100 oil
objective lens and processed by Adobe Photoshop version 7.0.
RESULTS
Mass Spectrometry Following a Pull-down Assay—Platelet
proteins were precipitated by the N-terminal SH3 domain of
CrkL, expressed as a GST fusion protein, and subjected to
SDS-PAGE analysis followed by Coomassie Brilliant Blue
staining. A 140-kDa band was observed, which was consis-
tently precipitated by GST-CrkL but not GST alone. A mass
spectrometry analysis following trypsin digestion revealed that
the 140-kDa band contained several peptides derived from the
human homologue of mouse ASAP1 (KIAA1249 clone) (Fig.
1A). The anti-ASAP antibody consistently recognized the 140-
kDa protein precipitated by GST-CrkL (Fig. 1B, left panel).
Furthermore, ASAP1 was also specifically immunoprecipitated
from platelet lysates by anti-CrkL antibody, indicating the in
vivo interaction of CrkL with ASAP1 (Fig. 1B, right panels).
Translocation of ASAP1 Following Platelet Activation—We
next examined whether ASAP1 translocates to the Triton
X-100-insoluble pellets in activated platelets, which represent
the operationally defined actin cytoskeleton (15, 16), as re-
ported for CrkL (5). We found that ASAP1 translocated to the
thrombin-activated actin cytoskeleton depending upon platelet
aggregation (Fig. 1C). We also confirmed and extended our
previous observations that CrkL also translocates to aggrega-
tion-dependent Triton X-100-insoluble pellets (Fig. 1C). These
data suggest that the ASAP1-CrkL complex may be involved in
the organization of the actin cytoskeleton following platelet
aggregation.
The Localization of ASAP1 in Spreading Platelets—In glass-
activated spreading human platelets, most of ASAP1 was lo-
calized in the areas where stress fibers terminate (Fig. 2B). The
ASAP1-rich structures were also enriched with CrkL, Hic-5,
and phosphorylated FAK, suggesting that, in platelets, ASAP1
is accumulated at focal adhesions (Fig. 2, A, C, and D). This
result is consistent with the previous report of ASAP1 localiza-
tion in NIH3T3 cells (12). It should be noted that platelets
express Hic-5, a focal adhesions protein, instead of paxillin
(17). As the spreading of platelets on glass coverslips is also an
IIb3 integrin-dependent process (18–20), the data further
suggest that the ASAP1-CrkL complex is involved in reorgani-
zation of the cytoskeleton following ligation of IIb3 integrin.
As we cannot express proteins in platelets, we further investi-
gated the physiologic significance of the CrkL-ASAP1 interac-
tion in ectopic expression systems.
Ectopic Expression of CrkL and ASAP1 in COS7 Cells—
Wild-type CrkL and ASAP1 were overexpressed in COS7 cells.
CrkL was purified from cell lysates by immunoprecipitation.
The immunoprecipitates were subjected to Western blotting
following SDS-PAGE analysis. FLAG-tagged CrkL and ASAP1
were present in the CrkL immunoprecipitate, and the immu-
nizing peptide for the CrkL antiserum strongly inhibited the
precipitation of both bands (Fig. 3A), suggesting that CrkL and
ASAP specifically associate in COS7 cells. Both wild-type and
SH2-mutated CrkL were coprecipitated with ASAP1, suggest-
ing that the intact SH2 domain is not necessary for CrkL-
ASAP1 interaction (Fig. 3B). Next, we examined the effects of
CrkL overexpression on the localization of both endogenous
ASAP1 and CrkL. In the cells where CrkL was not overex-
pressed, both CrkL and ASAP1, expressed at low levels, dif-
fusely distributed as small dots, which were relatively enriched
at the peripheral portion of the cells (Fig. 4A). However, on
uncoated glass coverslips, CrkL overexpression led to the for-
mation of peripheral focal adhesions, presumably through the
FIG. 2. Colocalization of ASAP1 with CrkL, phosphorylated-
FAK, and Hic-5 at focal adhesions. Platelets in diluted platelet-rich
plasma were allowed to attach and spread on glass coverslips, and were
fixed and stained for ASAP1, CrkL, phosphorylated FAK, Hic-5, and
F-actin as indicated.
FIG. 3. Specific association of CrkL with ASAP1 in COS7 cells.
A, ASAP1 and wild-type CrkL were overexpressed in COS7 cells. CrkL
was immunoprecipitated from the lysates with an anti-CrkL polyclonal
antibody. The CrkL-immunizing peptide (30 g/ml) was added during
precipitation as indicated. Replicate samples ( the immunizing pep-
tide) were separated by 7.5–15% SDS-PAGE, transferred to nitrocellu-
lose membranes, and then immunoblotted with an anti-FLAG mono-
clonal antibody (upper panel) or with an anti-CrkL polyclonal antibody
(lower panel). B, wild-type CrkL (lane 1) or SH2-mutated CrkL (lane 2)
was overexpressed with ASAP1 in COS7 cells. CrkL was purified from
the soluble extracts by immunoprecipitation, and the denatured sam-
ples were separated by 7.5–15% SDS-PAGE, transferred to nitrocellu-
lose membrane, and then immunoblotted with an anti-FLAG mono-
clonal antibody.
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CrkL-mediated increased avidity of integrin (21, 22) to adhe-
sive proteins in bovine serum adsorbed on glass coverslips.
Both CrkL and endogenous ASAP1 exactly colocalized at
these focal adhesions (Fig. 4B). It was reported that the
overexpression of ASAP1 led to destruction of focal adhesions
in NIH3T3 cells cultured on fibronectin-coated glass cover-
slips (14). Interestingly, the overexpression of ASAP1 and
CrkL did not inhibit the formation of focal adhesions or
colocalization of these proteins (Fig. 4B). CrkL is known to
accumulate at focal adhesions through its interaction with
Cas or paxillin, via its SH2 domain (1–3). In agreement with
the critical role of the SH2 domain, the SH2-mutated CrkL
did not induce the formation of peripheral focal adhesions or
accumulation of ASAP1 at the structures (Fig. 4C). The over-
expression of ASAP1 alone did not induce peripheral focal
adhesions and it was diffusedly distributed (Fig. 4D) as was
reported previously (14). It appeared that ASAP1 does not
disrupt focal adhesions if enough CrkL is present to accom-
modate ASAP1. In other words, overexpressed ASAP1 may
remove other CrkL ligands from focal adhesions. The prime
candidate of such molecules is C3G (4), which is a ligand for
CrkL and accumulates at focal adhesions, through its inter-
action with CrkL.
Overexpression of C3G Inhibits the ASAP1-CrkL Associa-
tion—C3G binds to CrkL through specific interaction of the
proline-rich domain of C3G with the N-terminal SH3 domain of
CrkL (4). If ASAP1 binds to the N-terminal SH3 domain of
CrkL in vivo, then the overexpression of C3G should compete
with ASAP1 for binding to CrkL. The results shown in the Fig.
5 supported this hypothesis. The overepression of C3G inhib-
ited co-precipitation of ASAP1 and CrkL (Fig. 5), suggesting
that the binding of both proteins to CrkL may be mutually
exclusive.
DISCUSSION
Despite the recognized importance of Arf in cell biology (8, 9),
the role of Arf in platelet function has received surprisingly
little attention. Our finding that ASAP1 is a novel CrkL ligand,
which may be involved in IIb3 signaling, should set the mo-
lecular basis for further studies on Arf and its GAPs in plate-
lets. Mass spectrometry analyses following two-dimensional
electrophoresis of platelet protein were performed, and the
presence of a number of hitherto undescribed platelet proteins
was reported (23, 24). Our approach confirms that mass spec-
trometry is indeed a powerful approach to identify platelet
proteins. Furthermore, our approach also employs a pull-down
assay before mass spectrometry, thus enabling us to identify a
novel protein-to-protein interaction.
The mechanisms of accumulation of ASAP1 at focal adhe-
sions were unclear. Our data suggest that CrkL is one of the
carriers of ASAP1 to focal adhesions, not ruling out the possi-
bility that adapters like Crk (1–3) have similar roles in other
situations. Recently, Liu et al. (25) reported that ASAP1 di-
rectly binds to FAK and suggest that ASAP1 may be a compo-
nent of multimolecular complexes at focal adhesions. The over-
expression of wild-type ASAP1 reportedly retarded the
spreading of REF52 cells plated on fibronectin (25). The over-
FIG. 4. Fluorescence micrographs showing the localization of
ASAP1 and CrkL in COS7 cells. COS7 cells were allowed to attach
and grow on glass coverslips overnight and were transfected with ex-
pression vectors. After a further overnight incubation, the cells were
fixed and stained for CrkL and ASAP1 as indicated. A, wild-type CrkL
was overexpressed. B, both wild-type CrkL and ASAP1 were overex-
pressed. C, both SH2-mutated CrkL and ASAP1 were overexpressed. D,
only ASAP1 was overexpressed and identified by a monoclonal anti-
FLAG antibody.
FIG. 5. Overexpression of C3G inhibits the association of CrkL
with ASAP1. Wild-type CrkL was co-expressed with C3G (lane 1),
ASAP1 (lane 2), or both (lane 3). The Triton X-100-soluble extracts (20
g/ml/lane) were denatured and subjected to SDS-PAGE followed by
immunoblotting. Five separate membranes were prepared and treated
with anti-FLAG, anti-C3G, anti-CrkL, or anti-ASAP1 antibodies as
indicated. B, CrkL was purified from cell lysates separated by 7.5–15%
SDS-PAGE, transferred to nitrocellulose membranes, and the mem-
branes were then immunoblotted with anti-ASAP1, anti-C3G, or with
anti-CrkL antibodies as indicated.
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expression of a truncated variant of ASAP1 unable to bind to
FAK resulted in a less pronounced inhibition of cell spreading
(25). These data suggest that while FAK is a major scaffolding
protein for ASAP1, there must be focal adhesions proteins
other than FAK responsible for localization of ASAP1. As CrkL
binds to paxillin or Cas, and locates at focal adhesions (1–3),
the adapter may contribute to “FAK-independent” functions of
ASAP1 at focal adhesions. Interestingly, it was recently re-
ported that the overexpression of ASAP1 inhibited spreading of
NIH3T3 cells, and the effect was independent of its Arf GAP
activity (26). It is possible that physical replacement of C3G by
ASAP1 is involved in such an effect. More recently, a RalBP1-
binding protein was shown to interact with mouse ASAP1 (27).
In the same report, the association of PAG2 (a human homo-
logue of ASAP1) and POB1 was demonstrated. It was sug-
gested that POB1 interacts with PAG2 through its proline-rich
motif, similar to FAK, thereby regulating cell migration. Taken
together, CrkL is a critical regulator of localization of ASAP1,
likely through its interaction with focal adhesions proteins like
paxillin or Cas, and, through cooperation with FAK and POB1,
the adapter may be critically involved in the regulation of the
cytoskeleton at focal adhesions.
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